首页> 外文期刊>Cureus. >Efficacy of Autogenous Bone Marrow Aspirate as a Fusion-promoting Adjunct to Anterior Cervical Discectomy and Fusion: A Single Center Retrospective Cohort Study
【24h】

Efficacy of Autogenous Bone Marrow Aspirate as a Fusion-promoting Adjunct to Anterior Cervical Discectomy and Fusion: A Single Center Retrospective Cohort Study

机译:自体骨髓穿刺作为颈椎前路椎间盘切除术和融合术的融合促进辅助剂的疗效:单中心回顾性队列研究

获取原文
       

摘要

Background Autogenous iliac crest bone marrow aspirate (BMA) has been shown to be a safe osteobiological adjunct to anterior cervical discectomy and fusion (ACDF), but little evidence exists to support its superiority to traditional methods. The object of this study was to retrospectively evaluate two cohorts of patients undergoing ACDF – with or without the use of BMA – in an effort to better characterize the clinical and radiographic outcomes associated with the use of BMA in ACDF. Methods The charts of all patients undergoing ACDF with a collagen-hydroxyapatite (CHA) sponge, local vertebral autograft and a polyetheretherketone (PEEK) interbody graft with or without BMA by a single staff neurosurgeon between 2011 and 2016 were retrospectively reviewed. Post-operative dynamic plain films and CT scans for each patient were reviewed and each instrumented level was independently evaluated for fusion over time. Results A total of 203 cervical levels were instrumented in 92 patients (with BMA, 52 patients, 122 levels; without BMA, 40 patients, 81 levels). The mean radiographic follow-up period was 21.4 ± 18.4 months, over which time 154 of 203 (75.6%) instrumented cervical levels were found to have fused (BMA group, 93/122 segments fused [76.2%]; non-BMA group, 61/81 segments fused [75.3%], p = 1). Kaplan-Meier survival analysis demonstrated a higher probability of fusion at any given time point for the BMA group when compared with the non-BMA group (p 0.001, log-rank test). Conclusions BMA is a readily accessible, low-cost adjunct to ACDF that enhances the fusion rates seen with a CHA/PEEK allograft combination.
机译:背景技术自体骨骨髓抽吸物(BMA)已被证明是前颈椎间盘切除术和融合术(ACDF)的安全的骨生物学辅助手段,但几乎没有证据支持其优于传统方法。这项研究的目的是回顾性评估接受ACDF治疗的两组患者(无论是否使用BMA),以更好地表征与ACDF中使用BMA相关的临床和影像学结果。方法回顾性分析2011年至2016年间由一名单一的神经外科医师接受ACDF胶原蛋白-羟基磷灰石(CHA)海绵,局部椎体自体移植和聚醚醚酮(PEEK)联合或不联合BMA进行ACDF的患者的病历。回顾了每位患者的术后动态平片和CT扫描,并随时间独立评估了每种仪器的融合水平。结果92例患者共测量203例颈椎病(BMA 52例122例;无BMA 40例81例)。平均影像学随访时间为21.4±18.4个月,在此期间,发现203台仪器中的154台(75.6%)已检测到颈椎融合(BMA组,93/122段融合[76.2%];非BMA组, 61/81段融合[75.3%],p = 1)。 Kaplan-Meier生存分析表明,与非BMA组相比,BMA组在任何给定时间点的融合可能性更高(p <0.001,对数秩检验)。结论BMA是ACDF的一种易于使用的低成本附件,可提高CHA / PEEK同种异体移植组合的融合率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号